Thus, our study demonstrates how combination therapies comprising KRAS G12C and FAK inhibitors achieve synergistic anticancer effects while simultaneously reducing acquired drug resistance, potentially maximizing the treatment outcomes for cancers harboring KRAS G12C mutations. Here, PTK2 is linked to cancer.